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ABSTRACT 
Introduction: Liver pathology is an important contributor to the global burden of disease and is 
the eighth leading cause of death among South Africans.(1-3) Liver disease is particularly frequent 
in HIV-infected South Africans.(4, 5) The ongoing evolution of the HIV/AIDS epidemic of 
Southern Africa requires that the spectrum of liver disease in this region be well described and 
meticulously monitored.Objectives: The primary aim of this study was to describe the histological 
result of liver biopsies of patients attending the Helen Joseph Hospital (HJH). Methods: This was 
a cross-sectional, retrospective study. A review of medical records of adult patients admitted to 
the HJH, who had liver biopsies done from 1st January 2008 to 30th June, 2013 was performed. 
Results: 107 liver biopsies fulfilled the entry criteria of the study. Patients’ mean age was within 
±13.5 years of 41.9 years of age. Two-thirds (65.4%) were HIV-infected.  Of this group, 70% were 
severely immune compromised viz. CD4≤200 cells/mm3. Two-thirds (62.9%) of the HIV-infected 
were on ART. A definite and/or probable diagnosis was achieved in 72% of the entire cohort, 
where the single most frequent infectious pathogen was Mycobacterium tuberculosis (n=18/33, 
54.5%).Of the group with confirmed TB of the liver, a pre-biopsy diagnosis of hepatic TB had 
been made in only nine patients (50%). Eighty percent of those diagnosed with drug-induced liver 
injury (DILI) were HIV-infected. Exposure to either or both TB and antiretroviral drugs was 
frequent. HIV-infected women were three times more likely to experience DILI than infected men. 
Liver biopsy confirmed the diagnosis of all patients categorised as having malignancy, alcoholic 
liver disease (ALD) and non-Alcoholic Fatty Liver Disease (NAFLD), p=0.000. In addition, a high 
level of certainty was achieved with regard to the categories of Infection and DILI, p=0.000.  The 
causes of liver disease in the HIV-infected and the uninfected differed with regard to all the 
diagnostic categories studied. Specific and coherent antiviral management of those with hepatitis 
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B and C infections was weak or non-existent. Conclusions: In the era of a changing HIV epidemic, 
liver biopsy continues to provide diagnostic value to the management of both the HIV-infected 
and uninfected.  
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CHAPTER 1 
1.0 INTRODUCTION 
The liver is particularly vulnerable to metabolic, toxic, microbial, circulatory and neoplastic 
injury.(6) Liver pathology is therefore an important contributor to the global burden of disease. (1, 
2), In the 2010 Global Burden of Disease (GBD) Study, liver cirrhosis accounted for 2.0% 
(n=1,030 800) of deaths worldwide.(1) Although this condition is only the eighth ‘leading’ cause 
of death among South Africans, the incidence of liver disease in this population appears to be 
rising. (3, 7) In the United Kingdom (UK) as a cause of death, liver disease is now ranked fifth, 
after cardiovascular, stroke, chest diseases, and cancer. (7, 8) 
 
Two percent of deaths in the United States of America (USA) are attributed to liver disease. (9) 
Infection with the hepatitis B and C viruses (HBV, HCV), alcohol-related liver disease (ALD) and 
non-alcoholic fatty-liver disease (NAFLD) are the leading causes of these deaths. (10) NAFLD 
has become the most common liver disorder in industrialised countries, affecting 20-40% of North 
Americans and Europeans.(11-14) A subset of NAFLD, non-alcoholic steatohepatitis (NASH), is 
particularly aggressive, and affects 6-17% of the group. NASH carries the risk of progression to 
cirrhosis and to hepatocellular carcinoma (HCC). The incidence of NASH reflects the prevalence 
of overweight and obesity in the human community. In South Africa, more than 29% of South 
African men and 56% of women are classified as overweight or obese.(15) 
 
Drug-Induced Liver Injury (DILI) is difficult to manage, is associated with significant morbidity 
and mortality, and is an important cause of liver disease in South Africa.(16, 17)The dual 
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epidemics of Human Immunodeficiency Virus (HIV) and tuberculosis (TB) in Southern Africa has 
resulted in the exposure of large numbers of people to drugs that are hepatotoxins.(4, 16, 18) 
Nonetheless, liver disease itself is frequent in HIV-infected South Africans, whether or not 
exposed to ART or TB drugs, (4, 5) and liver biopsy is occasionally required to resolve diagnostic 
uncertainty in the care of these patients.(19) 
 
By the end of 2011, thirty-four million people (range, 31.4-35.9) worldwide were living with HIV, 
6.4 million of which were South Africans. (17) Globally and in Africa, greater numbers now access 
ART and live longer, yet remain susceptible to TB, opportunistic disease, comorbid conditions, 
and the diseases of aging. The prevalence of liver disease among these is expected to increase. (20) 
Chronic infection with the HBV and HCV is common in various parts of Africa. In Southern 
Africa, the background prevalence of infection with HBV is high, 5-17 percent. While the 
prevalence of HCV in this region is low (<1%), effective oral treatment has recently become 
available to some in Southern Africa.(21-23) Dual infection with HIV and either HBV or HCV 
renders patients at greater risk of progressive liver disease. (18, 24) The expansion of therapeutic 
options and the growing pressure on manufacturers to provide affordable drugs provides hope that 
all in need will eventually access appropriate treatment. 
 
TB is the most frequent cause of death of HIV-infected Africans (25), where its presence is easily 
missed in those with advanced HIV. Undiagnosed TB was found in 50% of HIV-infected Kenyans 
at the time of autopsy. The TB was disseminated in 80 percent of these cases. Fifty percent had 
evidence of liver involvement viz. hepatic granulomas.(26) TB treatment predisposes patients 
especially the HIV infected to elevations of liver enzymes, and the onset of DILI.(27, 28) 
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Occasionally, abnormal liver tests following the start of ART, signal the onset of an unmasking or 
paradoxical ‘immune reconstitution inflammatory syndrome’ (IRIS). Both DILI and TB-IRIS can 
be life-threatening. Both cause diagnostic uncertainty. Liver biopsy is sometimes useful in 
resolving the dilemma.(29, 30) 
 
Most clinicians view liver biopsy as the ultimate tool with which to confirm a problem diagnosis. 
(31) But liver biopsy has its limitations. Firstly, obtaining an adequate tissue-core is operator 
dependent; then, sampling errors arise when lesions are small or few or where radiographic biopsy-
guidance is unavailable; furthermore, the biopsy may not be representative. Histology can be non-
specific and non-diagnostic, e.g. drug and toxin-induced injury, overwhelming sepsis; system-
defects are frequent and bias defines the patient population; people requiring liver biopsy have 
failed easier attempts at diagnosis and are often ill with comorbid conditions, and in receipt of 
multiple, potentially toxic drugs; randomised controlled studies are not done in this study 
population; and there are no ‘controls’. Notwithstanding these impediments, the constant evolution 
of health care in Africa and in particular, the fluid nature of the HIV/AIDS epidemic, demand the 
clearest description of disease and its meticulous monitoring. It is in this context that this study 
has been undertaken. 
 
1.1 AIMS AND OBJECTIVES 
1) To describe the histological diagnosis of liver biopsy specimens of patients attending the 
Helen Joseph Hospital between January 2008 – June 2013.  
2) To tabulate the indications for liver biopsy. 
3) To ascertain the demographic characteristics of patients who have had a liver biopsy. 
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4) To describe the results of liver function tests (LFTs) taken at the time of the liver biopsy. 
5) To describe the liver biopsy findings of a subgroup of patients with tuberculosis-related 
drug-induced liver injury (TB-DILI). 
6) To compare liver biopsy findings in the HIV-infected and the HIV-uninfected. 
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CHAPTER 2 
2.0 METHODS 
2.1 STUDY DESIGN 
This is a cross-sectional, retrospective study. We performed a record review of all adult patients 
admitted to the Helen Joseph Hospital (HJH), who had liver biopsies done from 01.01.2008 to 
30.06.2013. 
2.2 STUDY SETTING 
The HJH, in Johannesburg, South Africa, is a tertiary-level public hospital that forms part of the 
teaching-hospital complex administered by the state, and supported by the University of the 
Witwatersrand and its Medical School.  
2.3 STUDY POPULATION 
Patients who attend the HJH are mostly residents of the cities of Johannesburg and Soweto in the 
Gauteng Province, South Africa, where a small number are referred from distant clinics and 
hospitals, and the occasional patient is a visitor from a neighbouring country in the southern 
African region.    
2.3.1 Sample Size 
Convenience sampling was applied and included all adult patients who had liver biopsies done at 
Helen Joseph hospital, and who met the selection criteria. 
2.3.2 Selection Criteria 
 2.3.2.1 Inclusion Criteria 
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1- Adult patients (age >18 years)  
2- Patients who had had a liver biopsy during the time period 01.01.2008, 30.06.2013 and for 
whom medical records and a liver histology result were available for assessment. 
2.3.2.2 Exclusion Criteria 
 
1- Patient hospital record/file not retrievable 
2-Liver biopsy sample ‘inadequate’ or unavailable for histological assessment 
2.4 STUDY MEASUREMENTS 
Demographic data included the subject’s gender and age at the time of the liver biopsy. Where 
available, the following additional information was retrieved from the patient notes, viz. the 
patient’s HIV status, the most recent CD4 cell count i.e. within 6-12 months of the time of the liver 
biopsy, alcohol use, traditional medication and recreational drugs, the indication for the liver 
biopsy and the clinically suspected diagnosis prior to the biopsy, the use of prescribed drugs such 
as co-trimoxazole, antiretroviral therapy (ART), anti-TB treatment; and other antimicrobials. 
Laboratory parameters included the patient’s hepatitis A/B/C status, liver function tests (LFTs) 
and the international normalised ratio (INR), the full blood count (FBC), renal function tests e.g. 
the urea and electrolytes and the estimated glomerular filtration rate (eGFR), histology, serology, 
microscopy, cultures, and tests to diagnose sepsis including tuberculosis (TB). Acute blood tests 
such as the FBC, and renal and liver function tests, were taken as close as possible to the time of 
the biopsy, and therefore do not necessarily reflect admission results. Where available or known, 
the Child-Pugh score (CPS) was recorded. Furthermore, data on the clinical outcome, the presence 
of co-morbidities, as well as pertinent radiological data, such as the abdominal sonar and/or the 
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report of an abdominal CT scan, were collected. The CT scans and liver histologies were reviewed 
and reported on by a senior member of the radiology and histopathology departments of the 
University of the Witwatersrand medical school and/or the National Health Laboratory Service 
(NHLS), based at the Helen Joseph hospital or the National Institute for Communicable Diseases 
(NICD), Johannesburg. The data was collected from the original CT scan and histopathology 
reports and no further review with the investigator was done as part of this study. 
2.5 STUDY IMPLEMENTATION 
Each patient’s file was reviewed for the required information. Additionally, the patient’s clinical 
course, management, outcome, and, if available, follow-up data, were noted. The liver biopsy and 
laboratory results were obtained from the NHLS database based on the original histological report 
without any further clinical interpretation. Once retrieved, all data was captured on a data-
collection sheet (Appendix A). All patient-identifying data was removed between initial retrieval 
and recording in the database. Anonymised information from the data collection sheet was 
captured onto a Microsoft Excel™ spreadsheet to form the database of the study.  
2.6 ETHICS APPROVAL 
Ethics approval was obtained from the Human Research Ethics Committee (HREC) of the 
University of Witwatersrand-clearance certificate number M121197. Approval was sought and 
obtained from the Chief Executive Officer (CEO) of the HJH to review patient files. Professor 
M.J. Hale, Head of the Department of Anatomical Pathology at NHLS/University of the 
Witwatersrand, granted permission to review the liver histology results. 
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2.7 STATISTICAL ANALYSIS 
Data was imported from the MS-Excel™ spreadsheet into a statistical software package, viz. 
STATA version 12. A descriptive analysis was chosen to summarise the patients’ demographic, 
clinical, laboratory and radiological characteristics. Categorical variables such as gender have been 
characterised as frequencies and percentages. Normally distributed variables, such as age and lab 
results, e.g. LFTs, are represented as means and standard deviations. The data is presented in 
frequency tables, bar graphs and pie charts. Medians and inter-quartile ranges have been 
determined for abnormally distributed data. The Chi-square test was chosen to describe 
associations between two categorical variables and significance was set at a value of p<0.05. 
The liver function tests are grouped into four categories, based on the predominant pattern of liver 
enzyme derangement, as per the ratio (R) of ALT to ALP levels (expressed as multiples of the 
upper limit of normal, ULN): (19) 
• Cholestatic pattern (ALT/ULN: ALP/ULN, R<2) 
• Hepatocellular pattern (ALT/ULN: ALP/ULN, R>5) 
• “Mixed” pattern (R= 2-5)  
• Normal (ALP and ALT: R<1.3xULN) 
The Child-Pugh score (CPS) was calculated as per the accredited system.(32) 
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CHAPTER 3 
3.0 RESULTS 
3.1 PATIENT CHARACTERISTICS 
During the study period of 2008-2013, 401 liver biopsies were performed at the Helen Joseph 
Hospital. Two-hundred and ninety-four had to be excluded, because patient records could not be 
found. Hospital records were available for the remaining 107 patients. Liver biopsies were 
performed to identify the cause of persistently abnormal liver function tests in patients who were 
otherwise well (patients who were found to have deranged liver function tests and were not 
resolving with no cause that could be established) (n=29, 27.1%), or to assist in the diagnosis of 
ill patients with deranged liver function tests (n=78, 72.9%). Fifty-six (52.3%) patients were 
female, and 51 (47.7%) were male, a gender ratio of 1.1:1. Ages ranged from 18-84 years, but the 
mean age was 41.9±13.5 years, and was the same for men and women. A third (30.8%) were aged 
from 31-40 years and half (51.4%) were ≤40 years. (Table 1, Figure 1) 
Two-thirds of the group (n=70/107, 65.4%) was infected with HIV. The HIV status of 11 (10.2%) 
was unknown. Two-thirds of the HIV-infected (n=44/70, 62.9%) were on ART. Seventy percent 
of the group of infected subjects had a CD4 count below 200 cells/mm3. The mean CD4 count of 
the entire group was only 95 cells/mm3. Most were on a ‘first-line’ regimen, comprising two 
nucleoside/tide reverse transcriptase inhibitors (NRTIs) and one non-nucleoside reverse 
transcriptase inhibitor (NNRTI). Eighty percent (n=31/44) were on efavirenz (EFV). Only two 
(n=2/44, 5.2%) were on nevirapine (NVP). Six (n=6/44, 15.4%) were on a lopinavir/ritonavir 
(LVP/r, aluvia) protease inhibitor-based second-line regimen. The nucleoside/tide backbone 
comprised standard combinations of tenofovir, zidovudine, abacavir and lamivudine, drugs not 
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usually associated with hepatotoxicity. The antiretroviral regimen of five is unknown. The mean 
duration on ARTs before liver biopsy was 55.2 weeks (3-240).  
Twenty-four (n=24/107, 22.4%) were on anti-tuberculous medication (TB-drugs). All except one, 
were HIV-infected. Nineteen (n=19/24, 79.2%) were on both anti-tuberculous and ART 
medication. Seven (7/24, 29.2%) were on Rifinah (Isoniazid and Rifampicin), while seventeen 
(17/24, 70.8%) were on Rifafour (Isoniazid, Rifampicin, Pyrazinamide and Ethambutol). 
Concurrent exposure to cotrimoxazole (Bactrim) was confined to the HIV-positive subjects, but 
did not include all of them, n=14/70, 20 percent. Co-infection with Hepatitis B and C viruses was 
confirmed in nine and three subjects, respectively. The clinical severity of the liver disease at the 
time of the biopsy was measured in 99 subjects by means of the Child-Pugh score (CPS). This was 
normal or near normal, viz. 6.3±1.4 (range: 3-11) in the majority. Concurrent HIV infection was 
frequent among subjects in each of the three CPS-severity grades viz. A, least severe (n=37, 66%), 
B, moderate severity, (n=24, 61.5%) and C, most severe (n=4, 100%). HIV positive status did not 
appear to influence the CPS-score (p=0.28) per se. A small number of patients were known to 
abuse alcohol (n=5), use recreational drugs (n=2) and to take African traditional medicines (n=3) 
regularly. 
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Figure 1 Age and HIV Status of Patients Undergoing Liver Biopsy 
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Table 1 Age, Gender, HIV Status, CD4 level and Antiretroviral Therapy (ART) Use 
Study Parameter Number, n (%) 
or Mean (±SD)  
HIV Positive: 
n (%) 
HIV Negative: 
n (%) 
Patients, n (%) 
 
107 (100) 70 (65.4) 26 (24.3) 
Age (yr., Mean/SD) 41.9±13.5 37.8±9.6 45.7±14.2 
Gender: 
Female n (%) 
Male      n (%) 
Male : Female ratio 
 
56(52.3) 
51(47.7) 
1.1:1 
 
*41 (73) 
*29 (57) 
 
*11 (20) 
*15 (29) 
HBsAg Positive 9 (8.4) 7 2 
Anti-HCV Positive 3 (2.8) 1 2 
Antiretroviral Therapy 
(ART) 
44/107 (41.1) 44/70 (62.9) N/A 
Cotrimoxazole (CTX, 
Bactrim®) 
14/107 (13.1) 14 0 
Anti-Tuberculous 
Medication  
24/107 (22.4) 23 (32.9) 1 (3.8) 
Child-Pugh Score 99/107 (92.5%) 6.3± 1.5 6.0±1.2 
 
SD = standard deviation; IQR= inter-quartile range. *Note that for some subjects, viz. four 
women and seven men, their HIV status is unknown.    
 
3.2 LABORATORY CHARACTERISTICS 
All blood test results in this study were the most recent prior to the biopsy: taken at the time of the 
liver biopsy, or within a two-week prior period (the liver function tests), or within a two month 
prior waiting period for all other blood tests.  
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3.2.1 Haemoglobin (Hb) 
Moderate and/or severe anaemia i.e. Hb 9.9-8.0g/dl (moderate) and ≤7.9g/dl (severe), was present 
in 42 of the 106 subjects (39.6%) tested. Most (n=35/42, 83%) were HIV-positive. Five (n=5/42, 
12%) were negative. The association of anaemia with HIV-infection was significant, and 
correlated with decreasing haemoglobin levels (p=0.006). (Figure 2) Patients with severe anaemia, 
viz. Hb. <7.9g/dl, were also more likely to have very low serum albumin levels i.e. albumin <25 
g/l (p=0.000). However, a direct association of anaemia with other indices of severe liver 
dysfunction, such as the INR (p=0.191) or an elevated Child-Pugh Score (p=0.257), was not 
confirmed. 
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Figure 2 Prevalence and Severity of Anaemia in Patients undergoing Liver Biopsy 
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3.2.2 Liver Function Tests (LFTs) 
Each patient’s biochemical/liver enzyme results were grouped into the following patterns: 
cholestatic/infiltrative, hepatocellular and mixed. Chapter 2.7, p. 8, (Table 2, Figure 3) HIV-
infected subjects formed the majority of individuals in each group. No particular pattern was 
characteristic of the HIV positive cohort, p=0.534. A small number (n=13/107, 12.2%) had normal 
liver enzyme levels at the time of the liver biopsy. The cholestatic/infiltrative pattern was the most 
frequent over all viz. n=61/107, 57%. This pattern with the addition of an elevated total bilirubin, 
characterised those on TB drugs, n=20/24 (83.3%). All were on rifampicin-based TB therapy. No-
one on TB drugs had a purely hepatocellular pattern, but three (12.5%) had a ‘mixed’ pattern and 
one had normal liver enzymes. Only seventeen (n=17/107, 16%) had a predominantly 
hepatocellular pattern, seven (n= 7/17, 41%) of these had a DILI. The remaining 13 DILI patients 
had either a cholestatic (n=8/20) or a mixed pattern (n=5/20). Sixteen patients (n=16/107, 15%) 
had a ‘mixed’ enzyme pattern.  
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Table 2 Baseline Serum albumin, Liver-Enzyme Patterns by HIV status at the Time of 
Liver Biopsy 
Study parameter Total group 
n (%) 
HIV positive 
n (%) 
HIV negative 
n (%) 
p-value  
Patients 107 (100%) 70 (65.4) 26 (24.3)  0.007 
Hepatic Biochemistry: Bilirubin-Enzyme Patterns 
Cholestatic/ 
Infiltrative   
61 (57.0) 42 (68.8) 12 (19.6)  0.224 
Hepatocellular  17 (15.9) 10 (48.8) 5 (29.4)  0.553 
Mixed  16 (14.9) 12 (75.0) 4 (25.0)  0.837 
Normal LFTs 13 (12.2) 6 (46.1) 5 (38.5) 0.145 
Liver Biochemistry at the Time of the Liver Biopsy 
Abnormal LFTs 94 (87.9) 64 (91.4) 22 (84.6) 0.477 
 Mean *(SD) Mean *(SD) Mean *(SD)  
Albumin (g/l) 25±7.6 23.6±7.6  28.2±7.4 0.074 
 
*SD = standard deviation;  
Note that this table does not include the biochemical data of subjects whose HIV status is unknown. 
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Figure 3 Liver Enzyme Patterns in the Cohort of 107 Patients Undergoing Liver Biopsy 
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Table 3 Statistical Likelihood that the Cholestatic Liver Enzyme Pattern Identified those 
Subjects with an Infective Cause of Liver Injury 
CHOLESTATIC PATTERN 
 Infection Present Infection Absent 
Cholestasis Positive 25 36 
Cholestasis Negative 8 29 
   
Sensitivity for Cholestasis 25/(25+8) 75.76% 
Specificity for Cholestasis 29/(29+36) 44.62% 
PPV 25/(25+36) 40.98% 
NPV 29/(29+8) 78.38% 
 
Legend: PPV = positive predictive value; NPV = negative predictive value. 
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3.2.3 Albumin and the International Normalised Ratio (INR) 
The mean serum albumin and INR levels for the entire group were 25±7.6 (g/l) and1.22 ±0.34, 
respectively. (Figure 4) Most of the HIV-infected cohort had severely depressed albumin levels 
i.e. serum albumin <25g/l, (n=37/67, 55%) compared with the HIV-negative group, (n=8/24, 33%, 
p=0.066). Three quarters (75%) of the HIV-infected, who had severely depressed albumins, had 
low current CD4 counts viz. <200 cells/mm3. No correlation was found between the serum 
albumin and the INR (p=0.222). A severely prolonged INR would have ruled out a liver biopsy. 
HIV-negative subjects were more likely to have normal serum albumin levels, viz. serum albumin 
>35g/l: n=3/24, 12.5%, than the HIV-positives, n=3/67, 4.5 percent. 
 
Figure 4 Serum Albumin Levels According to HIV and Antiretroviral Status 
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3.2.4 Hepatitis B and C virus 
Serological tests of hepatitis B and C status were available for 97 (90.7%) patients. Twelve (12.4%) 
had been exposed to either HBV or HCV.  Thirty-three percent (4/12) were also on TB medication. 
Three (3.1%) had antibodies to hepatitis C, one of whom had a dual infection with both HCV/HIV. 
Active hepatitis B was diagnosed in the remaining nine (9.3%), seven of whom were also infected 
with HIV. None of the seven had CD4 counts above 200 cells/mm3, despite concurrent use of 
lamivudine and tenofovir in four. Neither of the two HBV-infected, but HIV-negative was on 
tenofovir and/or lamivudine. Of the seven co-infected with HIV, only four 7.1%) were on full ART 
therapy. No subject was simultaneously infected with both HBV and HCV. No subject had a HBV-
DNA (viral load) level measured. Of the three with antibodies to HCV only two had had levels of 
HCV-RNA (viral load) checked. Detectable HCV was confirmed in only one. No subject with 
HCV infection had been placed on anti-HCV medication. 
3.3 LIVER BIOPSY CHARACTERISTICS 
To facilitate analysis, the data from the liver biopsy (the histological result) was organised into the 
following six aetiological categories. (Tables 4 and 5) 
• Infection 
• Drug-Induced Liver Injury(DILI) 
• Malignancy 
• Alcoholic Liver Disease(ALD) 
• Non-Alcoholic Fatty Liver Disease (NAFLD) 
• Other: a group of miscellaneous conditions 
The histology did not always provide a definitive diagnosis. Where additional data supported a 
specific aetiology, the following terms were used to characterise the final diagnosis: definite, 
probable or possible. See Appendix C for clarification of definitions. A definite and/or probable 
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diagnosis was achieved in almost three-quarters (72%) of the group: definite (n=30, 28.0%) and 
probable (n=48, 44.9%). (Table 4) The Infection category was the largest (n=33, 30.8%), followed 
by ‘other’ (n=29, 27%) and ‘DILI’ (n=20, 18.7%). The highest Child-Pugh scores i.e. those with 
the most severe liver disease, were found in ‘infection’ and ‘DILI’ categories. The single most 
frequent infectious pathogen identified was Mycobacterium tuberculosis (n=18/33, 54.5%). Active 
TB was exclusive to the HIV-infected group. Higher numbers of HIV-positive subjects (n=26/33, 
79%) occupied the infection category versus the HIV-negative, n=7/33, 21%.The cause of 
infection differed between these groups. Infections of the HIV-infected group reflected a 
background presence of HBV and HCV, as well as advanced immune compromise, viz. 
disseminated TB and HIV-cholangiopathy. HBV and HCV were present in the HIV-negative 
group too, but the dominant infections were pyogenic and parasitic. Similarly in the ‘other’ 
category, histologically-confirmed causes differed between HIV-positive and negative. Where 
HIV-infection (Table 5) advanced immune suppression, CD4 counts <200 cells/mm3 
characterised the HIV-positive subjects in the infection (69%), DILI (69%) and malignancy (71%) 
categories, but not the HIV-positive in the ‘other’ (40%) category. Moreover, in this category, liver 
histology was non-diagnostic* in 62% (n=18/29), i.e. in 17% (n=18/107) of the entire study cohort. 
Eighty percent (n= 15/18) of this ‘unknown’ group were HIV-positive. 
The categories, ALD and NAFLD, had the fewest subjects and the smallest percentage of HIV-
positive members. 
Malignancy was diagnosed in 15% (n=16/107) of liver biopsies. Seven were HIV-infected, n=7/16 
(44%). Four were uninfected (n=4/16, 25%) and the HIV-status of the rest was unknown, n=5/16, 
31 percent. Of the seven who were HIV-infected, five had advanced immune suppression with 
CD4 counts <200 cells/mm3. Four of the tumours were AIDS-defining viz. Large B-cell non-
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Hodgkin’s lymphomas (NHL), n=4/16, 25 percent. All were in HIV-infected subjects. Concurrent 
HBV or HCV infection was present in three (37.5%) of the patients with hepatocellular carcinoma 
(HCC).  Apart from the presence of non-diagnostic biopsies in the ‘other’ category, this group also 
contained a variety of unrelated and unusual conditions that could not have been diagnosed without 
biopsy. Concurrent infection with HIV was frequent in the ‘other’ category as well. 
Table 4 Liver Histology Categories by HIV Status 
Histological  
Categories  
Number  
(n, %) 
Age 
(yr) 
      HIV Status (n=107) 
   HIV+ve 
(Total) 
CD4 Level 
(HIV+ve) 
HIV-ve 
 
HIV 
Status 
Unknown    <200 
(%) 
200-
350 
(%) 
>350 
(%) 
ALD 5 (4.7) 54.2±15.6 0 0 0 0 3  2  
DILI 20 (18.7) 37.6±10 16* 11  2  2  3  1  
Infection 33 (30.8) 37.9±9.6 26* 18  2 3 7  0 
Malignancy 16 (14.9) 49.1±15.5 7 5 1 1 4  5  
NAFLD 4 (3.7) 44.8±22 1  1   0 0 2  1  
Other 29 (27.1) 43.1±14.3 20* 8 6 1 7  2  
Total  107 
(100) 
41.8±22 70* 42 11 7 26 11 
 
ALD=alcoholic liver disease; DILI=Drug-induced liver injury; NAFLD=non-alcoholic liver 
disease. *NB. Individual CD4 count results were not available for all of these subjects.  
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3.3.1 Liver Biopsy, Histology and the Diagnosis of Infection 
Thirty-three of the 107 patients in this study (30.8%) had an identifiable infectious cause of their 
liver disease. The diagnosis was definite in nine, probable in 18 and possible in six. Although 
tuberculosis (TB) was the most frequent single infection found in this study, several additional 
infections are identified in Table 5. The infectious causes tabulated under the HIV-infected and 
uninfected columns differ. No subject of unknown HIV status had liver histology fitting the 
category ‘infection’ or ‘other’. Twenty percent (20%, n=5/26) had an HIV-associated 
cholangiopathy. A small number (n=10, 9.3%) had suspected or documented concurrent non-
tuberculous bacterial infections during their admission, i.e. prior to the liver biopsy. All were given 
antimicrobial therapy. Only four infections were bacteriologically confirmed viz. Escherichia coli 
(x2, blood and urine), Enterobacter cloacae (x1, blood), ESBL-producing Klebsiella pneumonia 
(x1, blood). None were believed to be responsible for the histological changes on liver biopsy. 
Most (80%) responded to antimicrobial therapy.  
*ESBL = extended-spectrum beta-lactamase producing organism 
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3.3.2 Liver Biopsy, Histology and Concurrent Tuberculosis 
Histological examination suggested tuberculous infection of the liver in 18 (16.6%) patients. 
(Table 5) However the acid-fast bacillus (AFB/Ziehl-Neelsen) stain was positive in only four 
histology samples. The diagnosis of TB was suggested by the presence of hepatic granulomas in 
the remaining 14. Microbiologically, infection with TB was confirmed on culture or with a Gene-
probe assay [GeneExpert (GXP) test] of non-hepatic tissue in 14, but in only nine (64.3%) was TB 
microbiologically confirmed (culture/GXP) to be in the liver itself. Of the 24 who were taking 
anti-tuberculous medication (TB drugs) immediately prior to the liver biopsy, only 10 (41.7%) had 
biopsy evidence supporting direct infection of the liver with TB. Only one on TB medication prior 
to the liver biopsy was HIV-uninfected, p=0.002. (Table 1) Nine of the 18 (50%) patients with TB 
in the liver-biopsy sample (above) had not been diagnosed with TB nor had TB drugs been started 
prior to the biopsy. Of the 24 on TB drugs at the time of biopsy, liver biopsy supported a diagnosis 
of DILI in 6 (25%). Of those with DILI, the mean duration of TB treatment prior to the liver biopsy 
had been 3.3 months ±1.5 SD. The frequency of DILI was unaffected by the TB regimen, i.e. 
rifafour or rifinah. Nonetheless, the concurrent use of TB drugs did confer a risk of DILI, p=0.001. 
The majority of those on TB drugs and those with confirmed TB infection of the liver, displayed 
a cholestatic/infiltrative liver enzyme pattern, n=20/24, 80%, p=0.015 derived by chi-square, and 
n= 15/18, 88.2%, p-0.012 derived by fishers exact, respectively.  
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3.3.3 Liver Biopsy, Histology and Drug-Induced Liver Injury, DILI 
Twenty patients were diagnosed with drug-induced liver injury (DILI). A clinical diagnosis of 
DILI had been made in only 13 prior to biopsy. The histology of 13 showed features of active TB 
(n=9), HIV-cholangiopathy (n=3) and viral hepatitis (n=1) in addition to DILI. Notwithstanding 
this and the fact that the histology of DILI is non-specific and that the diagnosis is usually one of 
exclusion, liver histology compatible with a diagnosis of DILI was determined to be ‘probable’ in 
90%, n=18/20.  (Table 5) Eighty percent (n=16/20, 80%) of the DILI subjects were HIV-positive. 
Women, many of whom were HIV-infected and had CD4 counts ≤200 cells/mm3 (69%), were 
three-times more likely than men to be diagnosed with DILI. Of the twenty with DILI on histology, 
eight (40%) were only taking ARVs, five (25%) were on both ARVs and TB medication, and three 
(15%) were only on TB drugs. Two (10%) were on traditional (African herbal) medications. Drug 
data was missing for two patients. Of the 13 subjects with DILI who were on ART, most had been 
exposed to efavirenz viz. 10 (77%) EFV, two (15%) to NVP and one (7.7%) to LPV/r. No 
particular regimen appeared to confer a greater risk of DILI (p=0.354). The nucleoside/nucleotide 
‘backbone’ of the ART regimen did not appear to influence the risk of DILI. Additional data 
concerning DILI and the use of TB drugs is provided in Chapter 3.3.2 page 24 above. 
 
3.3.4 Liver Biopsy, Histology and Other Medical Categories 
With regard to the categories of malignancy, alcoholic liver disease and non-alcoholic fatty-liver 
disease, the liver biopsy enabled diagnostic certainty viz. definite and/or probable, to be reached 
in 100% viz. p=0.000. A high level of diagnostic certainty was also achieved with regard to the 
categories of infection and DILI, p=0.000. This certainty however was not possible with regard to 
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the category of ‘other’. Most were HIV-infected and many (40%) were significantly immune 
compromised viz. CD4 counts, <200 cells/mm3. Almost half of the patients had diagnoses that 
required liver biopsy, i.e. the diagnosis could not have been made without access to tissue 
microscopy. But for more than half, the liver biopsy was unable to establish a final tissue diagnosis, 
e.g. ‘liver disease of undetermined origin’ and ‘granulomatous disease of uncertain cause’. (Table 
5, page 27 below). 
Fifteen patients developed or were admitted with renal dysfunction. Ten were HIV-positive, but 
none were on ARVs. A small number were hypertensive (n=17/107, 16%), ten had type II diabetes 
(n=10/107, 9%) and three were obese and had dyslipidemia. A review of the medication taken by 
these patients failed to suggest a cause for their liver disease.  
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Table 5. The Histological Diagnosis and Assessment of Probability of 107 Liver Biopsies 
from 2008-2013 at the Helen Joseph Hospital, Johannesburg, South Africa 
Diagnostic 
category 
Diagnosis Number 
(n) 
HIV profile* % of 
total 
 + - un  
Infection Tuberculosis, TB (histological features and microbiology) 18 18 0 0 16.6 
HIV-associated Cholangiopathy 5 5 0 0 4.6 
Hepatitis B Virus Infection (active) 3 2 1 0 2.8 
Schistosomiasis of the Liver 3 0 3 0 2.8 
Hepatitis C Virus Infection (active) 2 1 1 0 1.9 
Pyogenic Liver Abscess 1  0 1 0 0.93 
Ascending Cholangitis 1 0 1 0 0.93 
Infection 
Total 
Definite Probable Possible 33    30.8 
9/33 (27.2%) 18/33 (54.6%) 6/33 (18.1%) 26 7 0 
DILI:  
Total 
Definite Probable Possible 20   18 
0/20 (0%) 18/20 (90%) 2/20 (10%) 16 3 1 
Malignancy Hepatocellular Carcinoma  8 1 3 4 7.4 
Non-Hodgkin’s Lymphoma 4 4 0 0 3.7 
Metastatic Adenocarcinoma 3 1 1 1 2.8 
Neuroendocrine Carcinoma 1 1 0 0 0.93 
Malign:  
Total  
Definite Probable Possible 16    14.9 
15/16 (93.7%) 1/16 (6.25%) 0/16 (0%) 7 4 5 
NAFLD/ 
NASH: 
Total 
Definite Probable Possible 4    3.7 
0/4 (0%) 4/4 (100%) 0/4 (0%) 1 2 1 
Alcoholic 
Liver 
Disease 
Alcoholic Fatty-Liver Disease 3 0 2 1 2.79 
Alcoholic Liver Cirrhosis 2 1 0 1 1.86 
ALD:  
Total 
Definite Probable Possible 5    4.7 
2/5 (40%) 3/5 (60%) 0/5 (0%)  1 2 2 
Other Autoimmune Hepatitis 2  1 1 0 1.86 
Cavernous Hemangioma 2 2 0 0 1.86 
Liver Congestion  2  2 0 0 1.86  
Granulomatous Hepatitis of Unknown Aetiology 3 3 0 0 1.86 
Iron Overload (Siderosis), Wilson’s Disease, Primary Biliary 
Cirrhosis, Hepatic Fibrocystic Disease e.g. *ADPKD, Cirrhosis of 
Unknown Aetiology  
1each=5    0.93 
each 
Liver Disease of Undetermined Cause 15 12 3 0 14.0 
Other: Total Definite Probable Possible  29    27.1 
4/29 (13.8%) 4/29 (13.8%) 21/29 (72.4%)    
 Definite Probable Possible      
Total (All)  30 (28%) 48 (44.8%) 29 (27.1%) 107    100 
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*ADPKD= Autosomal Dominant Polycystic Kidney Disease; DILI = Drug-Induced Liver Injury; 
NAFLD = Non-Alcoholic Fatty-Liver Disease; NASH = Non-Alcoholic Steatohepatitis. Un= 
Unknown. 
 
3.4 CLINICAL OUTCOME 
One hundred and one (94.3%) patients were alive at the time of discharge. Two died during 
admission, both succumbing to nosocomial sepsis. Another subject died of an unknown cause in 
the six-month period following discharge. Seventy-nine (74.5%) returned for their month follow-
up visit. The follow-up records of 22 (20.7%) were unavailable for review. 
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CHAPTER 4 
4.0 DISCUSSION 
Liver disease is a major cause of morbidity and mortality among HIV-infected people worldwide. 
(33, 34) Despite the fact that clinicians have a variety of non-invasive tools to assist with 
uncovering the cause of liver disease, uncertainty sometimes remains. Liver biopsy is often 
employed to resolve this uncertainty. Over the past four decades of the HIV epidemic, HIV-related 
disease has been changing in response to the introduction of ART and the improved control of 
HIV itself, and its related opportunistic diseases.(35, 36) This evolution of the epidemic has 
resulted in enhanced survival, the ageing of the infected, and the emergence of comorbid disease 
in many. The nature of liver disease in this group of patients has changed over the years. (36) 
The burden of HIV infection among South Africans is considerable. Approximately 7.1 million 
(13%) are infected, previously estimated at about 12.5 percent.(37, 38) Data on liver disease in 
South Africans who are HIV-positive is limited to a small number of descriptive reports (39-42), 
where there is a need for additional data. It is within this context that this retrospective study was 
undertaken. The primary goal of the study is to tabulate the histological result of liver biopsies 
over a period of five-and-a-half years from 01 January 2008, until 30 June 2013. The study subjects 
were drawn from patients admitted to the Helen Joseph Hospital in Johannesburg, South Africa. 
The subjects were collected from consecutive liver biopsy records of the hospital and the database 
of the hospital’s pathology service, viz. The National Health Laboratory Service of South Africa 
(NHLS). Secondary objectives included the construction of a clinical and laboratory profile that 
describes the characteristics of the study cohort. This incorporates the following: age, gender, HIV 
status, Child-Pugh Score, hepatitis serology, and at the time of the liver biopsy, the subjects’ 
haemoglobin, serum albumin, and the pattern of the liver enzymes. The biopsy results were broadly 
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categorised as infective, DILI, alcohol-related, malignancy, non-alcoholic fatty-
liver/steatohepatitis, and a miscellaneous group ‘other’. Within these categories, patients were sub-
divided into a ‘final’ diagnostic group e.g. tuberculosis, hepatocellular carcinoma etc., based on 
the histology (biopsy) result. Where HIV status was known, results of the infected and uninfected 
were compared. The HIV status of a small number in the study was unknown. 
The mean age of the cohort was 42 years, where sixty-five percent were HIV-positive. The mean 
age of the latter was 37.8 years and was lower than that of the uninfected, viz. 45.7 years, p=0.000. 
This finding is consistent with similar studies in regions where HIV-prevalence is high.(35, 39, 
41, 43)The gender ratio was reversed: the HIV-uninfected were mostly male, 57%, while the HIV-
infected were mostly female, 58 percent. Women are over-represented in the HIV epidemic of 
Southern Africa. (37)The HIV-infected women in this study were at a three-fold increased risk of 
drug-induced liver injury (DILI), when compared with the infected males. Although the reason for 
this is not apparent from the data, HIV-infected women are at risk of DILI from nevirapine use if 
their CD4 counts are ≥250 cells/mm3.(44, 45). Few were exposed to nevirapine in this study, 
however, many were receiving other hepatotoxic drugs viz. efavirenz, protease inhibitors, 
ritonavir, TB drugs, trimethoprim-sulfamethoxazole. Growing evidence suggests that South 
African women may be at increased risk, because of alterations in genes controlling the expression 
of cytochrome CYP2B6 and the enzyme N-acetyltransferase 2 (NAT2). It is speculated that 
polymorphisms in these genes result in a ‘slow-metaboliser’ phenotype i.e. women who have an 
inability to clear efavirenz rapidly, have unusually high serum efavirenz levels, and have prolonged 
in-vivo activity of isoniazid and rifampicin when on efavirenz. Many of female subjects were on 
these agents. Studies in HIV-infected Cambodians on ART and TB drugs have revealed a similar 
group at increased risk of liver disease. (46-48) 
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The HIV-infected patients were severely immune compromised. Two-thirds had been taking ART 
for a year before their biopsy. Nevertheless, most (70%) still had low CD4 counts. The mean CD4 
count of the group was only 95 cells/mm3 at the time of the liver biopsy. Almost all (83%) of the 
HIV-positive cohort were anaemic, and many had low serum albumin levels. Advanced immune 
suppression is also suggested by the histological categories to which the majority of the HIV-
infected belonged, viz. ‘infection’, ‘DILI’ and ‘malignancy’. Anaemia and low albumin levels 
occurred with similar frequency in those on ART and those who were HIV-infected, but pre-ART. 
The low albumin levels were unlikely to have resulted from liver disease. INRs were normal. Few 
Child-Pugh scores suggested severe liver disease. The anaemia, the low CD4 counts, and the low 
albumins, most likely reflect ongoing inflammatory activity in the HIV-positive cohort, where 
many of whom had concurrent TB, other infections and malignancy. Anaemia is a well-recognised 
sign of advanced HIV disease and of poor survival of the HIV infected.(49, 50) 
The HIV-uninfected group differed from the infected. Most (68%) had normal haemoglobins. 
Albumin levels below 25g/l were infrequent. The histological categories and final diagnoses 
differed too. TB was absent from the HIV-uninfected group. DILI was an unusual diagnosis in this 
group. Non-Hodgkin’s disease was absent from the HIV-uninfected. Despite the larger absolute 
numbers of HIV-positives, none had alcoholic liver disease. Although hepatic steatosis/fatty liver 
has been linked to HIV-positive status and to the use of ARVs, only one of the four with this 
diagnosis was HIV-infected. (51) Although some South African studies suggest a high frequency 
of hepatic steatosis in the HIV-infected, the study population was a hospitalised and relatively 
young cohort, without comorbid disease, and although many were on ART, few had taken protease 
inhibitors or ART long enough to permit the development of drug-induced steatosis. (39, 41) The 
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biopsies of 15% (n=16/107) revealed cancer. Though similar numbers were HIV-infected (n=7/16, 
44%), uninfected (n=4/16, 25%) or of unknown status (n=5/16, 31%), the cancers differed. 
Hepatocellular carcinoma predominated among the uninfected or unknown-status groups. Only 
one of eight with hepatocellular carcinoma was HIV-positive.  All four with non-Hodgkin’s 
lymphoma of the liver were HIV-positive. 
Infection of the liver characterised a third of the study population, and defined the largest category 
in the study. Mycobacterium tuberculosis was the single most frequently identified organism. The 
relationship between TB and HIV is what the World Health Organisation (WHO) calls a regional 
and global health emergency, a situation that shapes the daily experience of the health workers in 
Southern Africa.(43, 52-54) Most subjects (70%) in the ‘infection’ category were HIV-positive. 
All who had TB were HIV-infected. Three-quarters of the HIV-infected had TB. The diagnosis of 
TB had not been made prior to biopsy in half (n=9/18): a finding shared with other local 
studies.(55, 56) Liver disease occurred directly through infection of the liver by M. tuberculosis, 
and indirectly as a consequence of liver damage caused by the TB drugs. TB of the liver is a 
disseminated form of TB and correlates closely with advanced immunosuppression in the HIV-
infected. In a postmortem study of 39 HIV-positive patients on ART, Wong et al. (2012) found 
active TB in two-thirds (n=26, 66.6%). TB had spread beyond the lungs in all, and many had 
hepatic TB. The autopsies also uncovered additional causes of death in patients dying from TB, 
namely viral, bacterial and fungal infections, community acquired pneumonia, malignancy, etc., 
that had not been diagnosed ante mortem. (56) A larger postmortem review from another South 
African hospital reported similar findings. (55) Hepatic TB was the “leading opportunistic 
infection” among 301 consecutive liver biopsies reported from Cape Town in 2015.(39) Although 
the current study appears to place TB at the head of the causes of serious liver disease in HIV-
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positive South Africans undergoing liver biopsy, it ought to be emphasized that this was a 
retrospective study. Patients who were less sick or whose liver condition was easier to diagnose 
would not have needed a liver biopsy. These will not have been adequately represented in this 
sample of patients. Nonetheless, and in stark contrast, hepatic TB was not a diagnosis of our HIV-
negative subjects.  
Where possible, very effort has been made to confirm the diagnosis of hepatic TB 
microbiologically. Unfortunately, mycobacterial culture and/or the molecular identification of TB 
had not been performed on every biopsy sample. Consideration of the histological findings, the 
concurrent isolation of TB from both liver and/or other body sites, and the clinical response to TB 
therapy, allowed us to assign a ‘definite or probable’ outcome to all our cases. The study time 
period viz. 2008-2013, predated the routine use of molecular TB-identification tests e.g. 
GeneXpert, (GXP), and the urinary point-of care TB test, viz. the LAM (Lipoarabinomannan) Test.  
Only 11 subjects had TB confirmed by the GXP method. None had access to the LAM test. These 
tests facilitate the early diagnosis of TB, and have the potential to reduce the need for liver biopsy 
in future hospitalised patients in Africa. (57, 58)  A number of patients developed hepatic disease 
and TB shortly after starting ART. Although this suggests an ‘unmasking-IRIS’, supportive 
histological features such as multiple granulomas in each high-power field, and a background 
eosinophilic infiltrate, were not reported.(59) Furthermore the generally ‘flat’ CD4+ response to 
ART, together with absent pre and post-viral load data, leaves the diagnosis of IRIS possible, but 
not definite. The South African National HIV-guidelines discourage obtaining a baseline viral load 
i.e. before the start of ART. (42) Hence, no baseline viral loads of the 44 HIV-positive subjects on 
ART were recorded. Few had six or 12-month follow-up HIV-viral load measurements while on 
ART. 
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Twenty patients (19%) were diagnosed with DILI. DILI is a recognised cause of increased 
morbidity and mortality in the HIV-infected. (60) Most of the DILI patients (n=16/20, 80%) were 
HIV-positive and on ART. In the absence of viral load data the certainty of viral suppression, 
adherence to therapy and the efficacy of the ART is unconfirmed. Nevertheless, almost all had 
previous and current CD4 results, and clinical histories that provided information on the start of 
ART, the timing of the diagnosis of liver disease, and in the case of DILI, the clinical response on 
withdrawal of the offending drug(s).The HIV-positive women in this study appeared to be 
particularly at risk. Of those with a diagnosis of DILI, 15(75%) were women and 5(25%) were 
men. 
Many of the drugs to which our patients were exposed, despite being standard-of-care in southern 
Africa, are hepatotoxins viz. Efavirenz, the drug to which most were exposed, Lopinavir/ritonavir 
and Nevirapine, Rifampicin and Isoniazid, standard TB drug combination therapy, and 
Trimethoprim-sulfamethoxazole. TB drugs conferred a definite risk of DILI, P=0.001. 
Nonetheless, simultaneous exposure to more than one hepatotoxic drug was frequent e.g. ART and 
TB drugs. Further complicating the allocation of cause was the concurrent presence in several 
biopsy samples of pathology unrelated to the DILI e.g. active TB, HIV-related cholangitis and 
hepatitis B virus infection. By comparison DILI was infrequent in the HIV-negative group 
(n=3/20, 15%), a group not exposed to either the ARVs or cotrimoxazole. Only one HIV-negative 
patient was on TB drugs at the time of their liver biopsy.  
Enzyme patterns did not correlate with specific causes of liver disease in this study. The 
cholestatic-pattern was frequently encountered among those with TB and HIV in the Infection 
category. But our analysis of sensitivity, specificity, and positive/negative predictive values failed 
to confirm a correlation. Clinicians often rely on liver enzymes when determining the likely cause 
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of a patient’s illness. The absence of a correlation is a reminder that a subset of patients will 
continue to require liver biopsy to clarify the nature of their hepatic disease, and that dependence 
on the pattern of enzymes for diagnostic purposes is likely to be misleading.  
Hepatic steatosis was seldom diagnosed. This contrasts with a number of other biopsy studies. (39-
41, 51, 61) There were too few cases and under-representation is likely. The patient base was 
drawn from an acute-care hospital, rather than a chronic-care, clinic-based facility. Many were 
young (<40 years) and were HIV-positive. A third were not on ARVs, and of those who were, few 
had sufficient exposure to the drugs usually associated with HIV-related fatty-liver/hepatic 
steatosis viz. stavudine and the protease inhibitors. Selection bias will have allowed an early 
clinical diagnosis with non-invasive tests (liver ultrasound), and the avoidance of biopsy in many 
patients. 
The hepatitis viruses –hepatitis B and C, and, rarely, E – are important causes of liver disease in 
Africa. (62, 63) Prevalence rates vary across the continent but all are encountered from time to 
time in South Africa. (64-66) A small number of our subjects were infected with HBV (n=9, 8.4%) 
and HCV (n=3, 2.8%). Although these numbers are small, they reflect the variable prevalence of 
HBV and the low prevalence of HCV in this region. (41) Prior selection would have removed the 
“stable but chronically infected” i.e. not in need of liver biopsy from the cohort. Most of the HBV 
group were dually infected with HIV (n=7/9, 77.5%). Although the numbers are small, effective 
therapy is now available: curative in the case of HCV, suppressive in the case of HBV. (67, 68) 
This group of patients is therefore important to find and manage well. 
No patient with HBV had their hepatitis viral load measured. In a recent cross-sectional study of 
rural Mozambicans and rural Zambians, 7.6% and 11.3% were HBV-positive, respectively. 
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(69)The authors noted that high HBV viral loads were frequent (49.4%) and correlated with an 
increased risk of hepatocellular carcinoma and of a poor response to HBV treatment. Recent data 
from rural South Africa has found a surprisingly large number of pre-ART individuals with 
“occult” HBV infection (15.1%) i.e. a detectable HBV-DNA and a negative HBsAg. Although this 
study suggests that infection with HBV or HCV is not of major importance in the context of liver 
biopsy, the absence of viral load monitoring in this group and limited exposure to any form of 
treatment implies ignorance with respect to the management of these patients. The current SA 
Department of Health (DOH) ART guidelines minimises the role of HBV in the context of HIV 
care. HBsAg tests are only recommended if liver enzymes (ALT) are elevated, or if a tenofovir-
based ARV first-line regimen is likely to be discontinued or changed. This is an era where HBV 
and HCV can be better managed, and where vaccination against HBV is safe, effective and 
affordable. Tenofovir has a role in the prevention of perinatal transmission of HBV. (70) The 
pricing of the new HCV-drugs is in flux, and likely to come down. This study is another call to 
clinicians in Africa to adopt a more supportive approach to the care of the HBV- and HCV-
infected. 
Sixteen of the 107 patients in this study had some form of liver cancer. Seven (44%) were HIV-
positive. The rest were either uninfected (25%) or had not been HIV-tested (31%).Severe 
immunosuppression (CD4<200 cells/mm3) again characterised most of the HIV-infected. All with 
hepatic non-Hodgkin’s lymphomas were HIV-positive, and had low CD4 counts. Hepatocellular 
carcinoma – a diagnosis traditionally associated with chronic HBV or HCV infection – was a 
disease primarily of the HIV-uninfected or “status-unknown”. A large multicenter North American 
HIV-cancer study has recently reported on 457 cancers in a cohort with 46,318 person-years of 
follow-up post-starting ART. (71)These investigators found the early occurrence of cancer–within 
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6 months of starting ART – to be a manifestation of ‘unmasking-IRIS’ involving AIDS-related 
tumours e.g. NHL of the liver as in our patients. (72) Rates of non-AIDS-related cancers in the 
American study increased continuously after starting ART and the authors suggest that these 
cancers reflect the accelerated aging of the HIV-infected (on ART) and the persistence of 
carcinogenic environmental triggers such as alcohol, HBV and HCV. Improved life expectancy 
and its corollary, aging, is expected to increase the annual cancer incidence in Africa to 1.4 million 
by 2030. (73-75) With regard to the current study, preventable and treatable infections are likely 
to have had a role in the development of three-quarters (n=12/16, 75%) of our patient’s tumours 
viz. HBV, HCV (hepatocellular carcinoma, HCC) and Epstein-Barr virus, EBV, (EBV/HIV-
related NHL). Currently, age-standardised 5-year net survival with liver cancer is poor, viz. 10-20 
percent.(76) If the outlook for liver cancer in Africa is to change, this study suggests that better 
attention to prevention – including HBV, HCV and HIV (and HIV/EBV), must be prioritised. 
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CHAPTER 5 
 
5.0 CONCLUSIONS 
 
This retrospective study reports on liver biopsy findings in both HIV-positive and negative subjects 
admitted to a Johannesburg teaching hospital over a five-and-a-half year period ending in July 
2013. Infection with HIV and its consequences dominate these results. The biopsy outcome is 
sorted into six categories: infection, drug-induced liver injury, malignancy, alcohol-related, non-
alcoholic hepatic steatosis and a miscellaneous category, ‘other’. The categories with the fewest 
numbers of patients – the alcohol-related and steatosis groups – were also the only categories 
where the HIV-uninfected predominated. HIV-infection was associated with anaemia, low serum 
albumins, and low CD4 counts despite normal/near normal measures of liver function, viz. the 
INR and the Child Pugh scores. Most of the HIV-infected had liver histology results that suggested 
ongoing inflammatory activity. Indeed, the largest category of the study was that of infection. 
Mycobacterium tuberculosis was the principle infecting agent and caused liver disease, both 
directly and indirectly, through TB drug use alone or in combination with ARVs. The comparison 
of the HIV-infected with those who were uninfected revealed two very different populations: 
different ages and genders, different infections, different drug exposures and different neoplasms. 
Biopsy results of the uninfected suggest the era before the HIV epidemic and provide an 
appreciation of the evolving nature of the epidemic. With regard to DILI, HIV-infected women 
were at increased risk and as discussed in the text, begging the question of a genetic predisposition. 
The confirmation of DILI on liver biopsy required ancillary clinical evidence. The retrospective 
nature of the study meant that we could do nothing with regard to the absence in the patient’s 
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records of post-ART initiation viral load measurements. Furthermore, the presence in DILI 
biopsies of additional and unrelated liver pathology is a reminder to clinicians to always keep an 
open mind when managing those suffering from HIV. Many of the patients included in this study 
belonged to this latter category. 
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CHAPTER 6  
 
6.0 STUDY LIMITATIONS 
 
This study has certain limitations. It was observational and retrospective in nature. Consequently, 
the data may have been subject to biases that were not fully appreciated. Incomplete clinical 
records were frequent and meant the exclusion of many potentially valuable cases that may have 
influenced the outcome of the findings. Records, when available, were sometimes incomplete, i.e. 
absence of follow up viral loads, and absence of HIV testing in some cases. Furthermore, the 
veracity of the data is also subject to observer bias, where the recording of liver enzyme patterns, 
the absence of outside/independent reporting of liver histology, clinical tests including radiology, 
and patient variables at times depended on numbers too small for statistical interpretation.  
 
Positive aspects of the study include its systematic collection of patient data and its comparison of 
two cohorts, the HIV-infected and uninfected, at a time when the HIV epidemic is moving towards 
its mature phase. Furthermore, findings of the study have potential value with regard to future 
patient management i.e. the role of molecular diagnostics, follow-up viral load monitoring in those 
on ART, HBV-viral load measurement in patients with chronic HBV infection. The study confirms 
the dominance of TB as a major cause of liver disease in the HIV-infected and reminds the clinician 
to constantly include this diagnosis, even when it appears to have been safely discarded. The study 
also reaffirms the role of liver biopsy when other avenues of diagnosis have been exhausted. Many 
conditions diagnosed with liver biopsy would not have been diagnosed in any other way. 
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APPENDIX 
Appendix A: Data Collection Sheet 
1.  Study number 
2. Date     
Demographic data 
3. Age: 
4. Gender:                   Male                    Female  
Clinical characteristics 
5.a) HIV status Positive          Negative            Unknown  
b) Most recent CD4 cell count before biopsy                       Date taken: 
………………………………….. 
6. Indication for liver biopsy (pre-biopsy diagnosis) i)………................................................... 
ii) Unknown  
7. Histological diagnosis on liver 
biopsy…………………………………………………………………………. 
i) Confirmed.................................................................. 
ii) Probable.................................................................... 
iii) Unknown......................................................... 
8. a) Use of ARVs  at time of diagnosis  Yes           No          Regimen: .................. 
i) NVP 
ii) D4T 
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b) Antibiotic    Yes               No               If Yes, specify which 
antibiotic……………………………            
c) Co-trimoxazole   Yes                               No  
9. a) Diagnosis of TB   Empiric          Confirmed         by.ex culture......................................    
b) Is the patient on Tuberculosis treatment?   Yes   No 
If yes, which ones…………………………………….and for how 
long:……………..days/weeks/months   
10. Sepsis. Blood stream infection         Confirmed          suspected         Not suspected 
Organism on blood culture............................................... 
11. Evidence of Renal dysfunction at time of admission:  
Normal             mild renal failure (egfr ‹50)          severe RF (‹20)  
 
12. Imaging 
Done                       Not done               
If done, what modality:   Abdominal sonar      CT abdomen          
Other:…………………………… 
Findings on imaging: 
a) Ascites:   Yes             No   
b) Lymphadenopathy           Yes            No   
c) Features of Fatty Liver:    Yes             No   
d) Features of Liver Cirrhosis: Yes           No      
e) splenic microabscesses   Yes              No 
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f) Others:           Yes               No                If yes,  
specify………………………………… 
13. Hepatitis studies: 
a) Anti-HAV  positive               negative 
b)HBsAg  positive               negative 
c) HBeAg                   positive               negative   
d) Anti-HBc  positive               negative 
e)Anti-HBs  positive               negative 
f) Anti-HbcIgM  positive                negative 
g)Anti-HBcIgG positive                negative 
h)Anti-HCV  positive                negative          
i) HBV or HCV viral load....................... 
14. Most recent (admission) liver function test before liver biopsy: 
Test Result 
Total Bilirubin  
Direct Bilirubin  
Alanine Transaminase  
Aspartate Transaminase  
Alkaline Phosphatase  
γ-GlutamylTransferase  
Serum Albumin  
INR  
Prothrombin Time  
 
15. Child-Pugh score     5-6              7-9                10-15    
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16. The most recent FBC before the biopsy 
White cell count  
Haemoglobin  
Platelets  
Eosinophils  
 
17. History of Alcohol abuse (˃4 units/day for men and ˃3 units/day for women)?                                        
Yes              No               unknown         
18. Traditional medication use before biopsy?        Yes           No          unknown 
19. Clinical outcome at discharge: Alive                 Dead               Unknown 
20. Follow-up at 3-6/12 post discharge:  Alive           Dead         Uknown            no follow-up 
21. Co-morbidities 
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Appendix B: Proposal of a Modified Child-Turcotte-Pugh Scoring System 
 1 point 2 points 3 points 4 points 
Original CTP*     
Bilirubin (mg/dL) <2         2–3 >3  
Albumin (g/dL) >3.5 2.8–3.5 <2.8  
PT prolong (sec) 
INR 
<4 4–6 > 6  
Ascites   None (Absent) Slight (Easily 
Controlled) 
Moderate (Poorly 
Controlled) 
 
Encephalopathy
  
None Grade 1–2 Grade 3–4  
 
Modified CTP† 
    
Bilirubin (mg/dL) 
(for cholestatic 
disease) 
<2 
(<4) 
2–3 
(4-10) 
3.1–8 
(>10) 
> 8 
Albumin (g/dL) > 3.5 2.8–3.5 2.3–2.7 <2.3 
PT prolong (sec) 
INR 
<4 4–6   6–11   >11 
Ascites None (Absent) Slight(Easily 
Controlled) 
Moderate(Poorly 
Controlled) 
— 
Encephalopathy None Grade 1–2 Grade 3–4 — 
 
*Original CTP class: A, 5–6 points; B. 7–9 points; C, 10–15 points. 
†Modified CTP class: A, 5–6 points; B: 7–9 points; C, 10–15 points; D, 16–18 points. 
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Appendix C: Definitions of Definite, Probable and Possible 
Definite: The agent (TB/ARV/TB drugs etc.) is confirmed as the cause of the disease or diagnosis 
(DILI, malignancy, impaired liver function tests etc,). The available evidence establishes/confirms 
a causal relationship i.e. an association exists between the agent and the event. Furthermore, there 
are plausible mechanism/features on biopsy that link the two together and rules out 
other/alternative causes. So, a definite diagnosis was recorded if a microbe that could reasonably 
have caused the liver disease was found in the liver on biopsy e.g. Schistosomiasis, or as in the 
case of tuberculosis, the hepatic histology revealed compatible changes, such as granulomas, 
caseation etc. and/or where organisms (acid-fast bacilli) were seen in the specimen while the 
organism itself was concurrently confirmed with culture, DNA probe, or urinary 
lipoarabinomannan (LAM), in the same body but at a different site, e.g. lung, blood and/or marrow, 
urine, lymph node or skin. 
Probable: It is likely that the event was caused by the agent (TB). The evidence favours 
acceptance of a causal relationship. However direct evidence linking one to the other is not 
available.  Nevertheless, the probability exists that the two are related, and that there is a plausible 
features on the biopsy that supports the proposition. So, a probable diagnosis was noted if the 
liver histology suggested a likely cause and additional clinical, radiographic and laboratory 
information supported this probability e.g. serology (HBV, HCV), miliary or cavitatory changes 
on chest x-ray, and/or granulomas in organs other than the liver (TB).  The difference between a 
definite and probable diagnosis was the absence of microbiological confirmation of the microbe 
in the probable group. 
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Possible: There is a reasonable possibility that features on biopsy and suggested agent or diagnosis 
can be linked together, but either the mechanism is unclear or the histological evidence is 
inadequate to confirm or exclude the diagnosis. An association between the two may be present, 
but a direct causal link between the two cannot be established. So, a possible diagnosis was 
considered when a microbiological cause could not be confirmed with certainty, but histology was 
compatible and where clinical, radiographic and laboratory data did not exclude the possibility of 
the diagnosis, but also did not conclusively support it, and where alternative causes were 
exhaustively excluded during the patient’s pre-biopsy workup. The difference between a probable 
and a possible diagnosis rests principally on the absence in the possible group of conclusive 
support from the ancillary investigations/workup. 
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